MAGE-A4/Survivin cancer vaccine (Bioimmulance)
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameMAGE-A4/Survivin cancer vaccine (Bioimmulance)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBioimmulance
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A